Furthermore, with the current development of more comprehensive NGS panels, with the inclusion of POLE, TP53 genes, MSI, and other putative actionable endometrial genes, we foresee that a single NGS methodology would be the most effective, quick, objective, and cost-effective approach for endometrial cancer molecular classification. This evidence concerns the gene POLE and endometrial cancer.